Innate Pharma S.A. Sponsored ADR P/FCF ratio

P/FCF ratio of IPHA for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/FCF ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its free cash flow per share. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low P/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current P/FCF ratio of Innate Pharma S.A. Sponsored ADR is 0.0 (as of December 30, 2020)
  • P/FCF ratio for the quarter ending December 30, 2020 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly P/FCF ratio decreased by NaN%
  • Annual P/FCF ratio for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual P/FCF ratio for 2019 was 0.0 (a NaN% decrease from previous year)
  • Annual P/FCF ratio for 2018 was 0.0 (a NaN% decrease from previous year)
Visit stockrow.com/IPHA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/FCF ratio of Innate Pharma S.A. Sponsored ADR

Most recent P/FCF ratioof IPHA including historical data for past 10 years.

Interactive Chart of P/FCF ratio of Innate Pharma S.A. Sponsored ADR

Innate Pharma S.A. Sponsored ADR P/FCF ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0 0.0 0.0
2019 0.0 0.0 0.0
2018 0.0 0.0
2017 0.0
2016 0.0

Business Profile of Innate Pharma S.A. Sponsored ADR

Sector: Healthcare
Industry: Biotechnology
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.